Key Highlights

● Shares were indicated at $429.73, up 3.13%, in Friday's 8:23 a.m. ET pre-market table.

● Second-quarter net sales rose 13.8% to $872.3 million with adjusted EPS of $2.37.

● Third-quarter guidance from July called for adjusted EPS of $2.14 to $2.24.

● Proprietary Products sales rose 16.6% to $722.6 million in the second quarter.

West Pharmaceutical Services (NYSE:WST) is moving higher before Friday's open. A pre-market table, refreshed at 8:23 a.m. ET, showed the injectable-drug packaging specialist at $429.73, up 3.13%.

Auto-generated market context for the stock cites a third-quarter beat and a raised full-year sales and EPS outlook. West had scheduled its third-quarter release for before the market opened on Thursday, October 29, so today's move would be a second-day reaction. The specific third-quarter figures could not be independently verified, so they are not reported here, and the link between the results and today's move is inferred.

What is known about the setup

West's last fully verified results were for the second quarter, reported on July 23. Net sales rose 13.8% to $872.3 million, with organic growth of 12.7%. Adjusted EPS was $2.37, up 28.8%. The company raised its 2026 outlook at that time to net sales of $3.345 billion to $3.380 billion and adjusted EPS of $8.85 to $9.05.

For the third quarter specifically, West guided in July to net sales of $820 million to $835 million and adjusted EPS of $2.14 to $2.24. Those are the benchmarks investors will use to judge the reported beat.

The second-quarter growth was driven by Proprietary Products, whose sales rose 16.6% to $722.6 million. That segment includes the high-value components that seal and protect injectable drugs, among them the GLP-1 obesity and diabetes treatments that have become one of healthcare's biggest growth markets. The contract-manufacturing segment, West Vantage, grew 2.0% and saw Margin pressure from a Cybersecurity incident.

There are also changes at the top. On June 1, West named Michel Lagarde president and chief executive, and on October 19 it declared a quarterly Dividend of $0.26 a share, payable November 18. That makes the October report one of the first under the new chief executive, which adds weight to any change in guidance.

Why the S&P 500 matters here

West is a member of the S&P 500 and part of its health care sector, which had a strong Thursday. The Health Care Select Sector SPDR (XLV) gained 2.4% to a record, according to market data, helped by Eli Lilly (NYSE:LLY)'s 6.4% jump after it raised its full-year guidance. Because West supplies packaging for injectable drugs, including incretin therapies, it often trades in sympathy with strong GLP-1 Demand signals.

That helps West stand out on a morning when tech-driven indexes are under pressure. S&P 500 futures were down about 1.1% and Nasdaq-100 futures about 2.6% at 7:56 a.m. ET market quotes, as investors reacted to Amazon (NASDAQ:AMZN)'s and Intel (NASDAQ:INTC)'s results.

Risks and what to watch

Second-day moves after Earnings can reverse once regular trading begins, and pre-market Volume is thin. Because the exact third-quarter figures and the size of the guidance increase have not been verified, the size of the beat remains unconfirmed. West's valuation is high relative to many medical-supply peers, which leaves less room for error. Its Vantage segment has had margin problems before. Investors will also want to see whether management's newly raised targets hold up as the year closes.

At the open, the test is whether health care's defensive strength continues to offset broader market weakness. Beyond today, the October jobs report on November 6 and any further readings on GLP-1 demand from drugmakers will be the main outside catalysts. West's fourth-quarter report, expected early in 2027, will show whether it meets its updated full-year outlook.